NKGN (NKGen Biotech) Total Assets : $15.00 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Total Assets?

NKGen Biotech's Total Assets for the quarter that ended in Sep. 2024 was $15.00 Mil.

During the past 12 months, NKGen Biotech's average Total Assets Growth Rate was -8.70% per year.

Total Assets is connected with ROA %. NKGen Biotech's annualized ROA % for the quarter that ended in Sep. 2024 was 172.25%. Total Assets is also linked to Revenue through Asset Turnover. NKGen Biotech's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

NKGen Biotech Total Assets Historical Data

The historical data trend for NKGen Biotech's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Total Assets Chart

NKGen Biotech Annual Data

Trend

Dec21

Dec22

Dec23

Total Assets

18.07

16.33

16.48

NKGen Biotech Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial					25.20	16.48	16.32	15.65	15.00

NKGen Biotech Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

NKGen Biotech's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-58.693	+	75.174
	=	16.48

NKGen Biotech's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	-47.05	+	62.045
	=	15.00

NKGen Biotech (OTCPK:NKGN) Total Assets Explanation

Total Assets is connected with ROA %.

NKGen Biotech's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	26.392	/	( (15.648	+	14.995)	/ 2 )
	=	26.392	/	15.3215
	=	172.25 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

NKGen Biotech's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	0	/	( (15.648	+	14.995)	/ 2 )
=	0	/	15.3215
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

NKGen Biotech Total Assets Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (OTCPK:NKGN) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.